NDA 205494 · Genzyme Corp
Cerdelga
Eliglustat Tartrate · Oral · Glucosylceramide Synthase Inhibitor
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Aug 29, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Aug 19, 2014
Approved uses
2
Original approval plus efficacy supplements
Registered trials
21
5 Phase 3, 2 recruiting
FAERS reports
1,659
480 serious, 21 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 3, 2024.
CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test [see Dosage and Administration (2.1) ] . CERDELGA is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test. ( 1 ) Limitations of Use : CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect. ( 1 ) A specific dosage cannot be recommended for CYP2D6 indeterminate metabolizers. ( 1 ) Limitations of Use : Patients who are CYP2D6 ultra-rapid metabolizers (URMs) may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect [see Clinical Studies (14) ] . A specific dosage cannot be recommended for those patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers) [see Clinical Studies (14) ] .
Mechanism: Gaucher disease is caused by a deficiency of the lysosomal enzyme acid β-glucosidase. Acid β-glucosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide. The enzymatic deficiency causes an accumulation of glucosylceramide (GL-1) primarily in the lysosomal compartment of macrophages, giving rise to foam cells or "Gaucher cells." The clinical features of this lysosomal storage disorder (LSD) are reflective of the accumulation of Gaucher cells in the reticuloendothelial system (liver, spleen, bone marrow, and other organs). The accumulation of Gaucher...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 29, 2018 Supplement 3 · Efficacy OrphanLabelLetterMedication Guide
- Aug 19, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanMedication GuideLetterLabel
1 products under this application
- CERDELGA · ELIGLUSTAT TARTRATE EQ 84MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Eliglustat" as an intervention, any sponsor and status, largest first.
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)Pivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01074944 · 170 participants · Start Jun 2010 · Primary completion Oct 2015
Drug: Eliglustat tartrate · For: Gaucher Disease
Sites: San Diego, California; New Haven, Connecticut; Decatur, Georgia · 46 sites in all
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)Pivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00943111 · 160 participants · Start Sep 2009 · Primary completion Nov 2012
Drug: Eliglustat tartrate; Imiglucerase · For: Gaucher Disease, Type 1
Sites: Beverly Hills, California; San Francisco, California; Aurora, Colorado · 34 sites in all
- GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.Pivotal-lookingRecruiting
Chinese PLA General HospitalAcademic, hospital or other
NCT06558773 · 120 participants (planned) · Start Mar 1, 2026 · Primary completion Mar 1, 2027
Drug: Regorafenib+Immune checkpoint inhibitor; Eliglustat+Immune checkpoint inhibitor and 1 more · For: Colorectal Cancer
Sites: Beijing, China
- Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT03485677 · 57 participants · Start Apr 11, 2018 · Primary completion Dec 26, 2025
Drug: Eliglustat GZ385660; Imiglucerase GZ437843 · For: Gaucher's Disease Type I; Gaucher's Disease Type III
Sites: Buenos Aires, Argentina; Calgary, Canada; Vancouver, Canada · 21 sites in all
Chinese PLA General HospitalAcademic, hospital or other
NCT07138547 · 40 participants (planned) · Start Dec 26, 2025 · Primary completion Aug 31, 2028
Drug: Eliglustat, CD30 target immunotherapy · For: Lymphoma
Sites: Beijing, China
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)Pivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00891202 · 40 participants · Start Nov 2009 · Primary completion Jul 2012
Drug: Eliglustat tartrate; Placebo · For: Gaucher Disease, Type 1
Sites: San Francisco, California; New Haven, Connecticut; Decatur, Georgia · 18 sites in all
SanofiSanofi (SNY)
NCT02536937 · 32 participants · Start Sep 2015 · Primary completion Jan 2017
Drug: eliglustat · For: Gaucher Disease
Sites: Miami, Florida; Saint Paul, Minnesota; Knoxville, Tennessee
- Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 StudiesPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02536755 · 31 participants · Start Oct 27, 2015 · Primary completion Jun 24, 2021
Drug: Eliglustat, GZ385660 · For: Gaucher Disease
Sites: Montreal, Canada; Moscow, Russia; Saint Petersburg, Russia · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- weight increased175
- product dose omission in error162
- weight decreased150
- fatigue79
- product dose omission issue76
- dyspepsia54
- arthralgia53
- fall53
- nausea51
- dizziness45
- off label use43
- covid-1942
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 7 |
| 2015 | 95 |
| 2016 | 47 |
| 2017 | 38 |
| 2018 | 68 |
| 2019 | 129 |
| 2020 | 78 |
| 2021 | 153 |
| 2022 | 251 |
| 2023 | 192 |
| 2024 | 178 |
| 2025 | 223 |
| 2026 | 200 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cerdelga (Eliglustat Tartrate)
2024 spending
$42.1M
Beneficiaries
142
1,437 claims
Per beneficiary
$296,243
$555.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $27,496,636 |
| 2021 | $31,935,141 |
| 2022 | $36,657,951 |
| 2023 | $37,570,025 |
| 2024 | $42,066,552 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.
Dong L, Cao Z, Chen M, et al. · Nat Commun 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease.
Leonart LP, Fachi MM, Böger B, et al. · Ann Pharmacother 2023 · Meta-Analysis, Systematic Review
- A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
Lukina E, Watman N, Arreguin EA, et al. · Blood 2010 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
Peterschmitt MJ, Freisens S, Underhill LH, et al. · Orphanet J Rare Dis 2019 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1.
Li J, Chen J, Kanamaluru V, et al. · Mol Genet Metab 2020 · Clinical Trial, Phase I, Multicenter Study
- Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
Cox TM, Drelichman G, Cravo R, et al. · Blood 2017 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.